Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)

Trial Details

NCT ID
NCT05305131
Phase
PHASE2
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • cisplatin and gemcitabine
  • induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • The participant (or legally acceptable representative if applicable) provides written consent for the trial.
  • Participants who are at least 21 years of age on the day of signing informed consent with histologically or cytologically confirmed diagnosis of no…
  • Have measurable disease based on RECIST 1.1.
  • Tumour stage III (except for T3N0 and T3N1) or IVA according to the American Joint Committee on Cancer (AJCC) 8th edition criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →